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Summary
The European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) established a joint task force with the purpose to
develop clinical evidence-based guidelines on evaluation of fitness for radical therapy in patients with lung cancer. The following topics were
discussed, and are summarized in the final report along with graded recommendations: Cardiologic evaluation before lung resection; lung
function tests and exercise tests (limitations of ppoFEV1; DLCO: systematic or selective?; split function studies; exercise tests: systematic; low-
tech exercise tests; cardiopulmonary (high tech) exercise tests); future trends in preoperative work-up; physiotherapy/rehabilitation and
smoking cessation; scoring systems; advanced care management (ICU/HDU); quality of life in patients submitted to radical treatment; combined
cancer surgery and lung volume reduction surgery; compromised parenchymal sparing resections and minimally invasive techniques: the balance
between oncological radicality and functional reserve; neoadjuvant chemotherapy and complications; definitive chemo and radiotherapy:
functional selection criteria and definition of risk; should surgical criteria be re-calibrated for radiotherapy?; the patient at prohibitive surgical
risk: alternatives to surgery; who should treat thoracic patients and where these patients should be treated?
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doi:10.1016/j.ejcts.2009.04.022The paper published in the July issue of the European
Respiratory Journal entitled ‘ERS-ESTS clinical guidelines on
fitness for radical therapy in lung cancer patients (surgery
and radiochemotherapy)’ [1] summarizes the work of the
joint task force created by the European Respiratory Society
(ERS) and the European Society of Thoracic Surgeons (ESTS).
The objective of this working group, which was composed ofSurgery. Published by Elsevier B.V. All rights reserved.
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Table 1
Summary of recommendations. For the complete list of recommendations and details of literature and grading please refer to the original paper [1]. Reproduced with
permission from Brunelli et al., European Respiratory Journal, 2009 [1].
Recommendations Level of
evidence
Grade of
recommendation
Who should treat thoracic patients and where they should be treated
The management of lung cancer patients must be performed by multidisciplinary teams
(a thoracic surgeon specialized in lung cancer, a medical oncologist, a radiation oncologist,
and a pulmonologist)
2++ B
The surgical treatment of lung cancer patients must be performed in specialized centers by qualified
thoracic surgeons, since specialization has been shown to have a positive impact on resectability,
postoperative mortality and long-term survival
2++ B
Surgical volume has been shown a positive impact on resectability, postoperative mortality and
long-term survival. Lung cancer surgery should be performed in centers with adequate volume of
cases (although volume thresholds reported in the literature varies in size and definition, a
minimum surgical volume of 20—25 major lung resections lobectomy or pneumonectomy per year
should be advised)
2+ C
Cardiac evaluation
Patients should be risk-stratified using validated risk indexes, which should direct any additional testing 2++ B
Patients with (a) poor functional status (<4 METS) and 1—2 RCRI criteria and (b) a history of angina or
claudicatio should be generally appropriate for noninvasive testing to assess risks for surgery
2++ B
Patients at >20% risk according to initial estimates (RCRI >3) may still have high perioperative risks despite
a negative noninvasive study (>5% post test probability with negative test)
2++ B
Patients with physical findings consistent with aortic outflow tract obstruction should have preoperative
echocardiography
2++ B
Preoperative echocardiography should also be obtained when other valvular disease, left ventricle
dysfunction, or pulmonary hypertension is suspected, according to published guidelines
2++ B
Few if any non-cardiac surgery patients must receive routine pulmonary artery catheterization 1++ A
Patients with ischemic heart disease generally do not benefit from newly prescribed perioperative beta blockade 1++ A
Beta blockers should be continued in patients who are already taking them 2++ B
Beta blockers may be beneficial as new therapy in very high risk patients 1 B
Prophylactic nitrates can reduce ischemia but not major events; prophylactic calcium channel
blockers could be of uncertain benefit
2++ B
Perioperative coronary revascularization. Patients at high risk clinically or based on noninvasive testing must
be considered for diagnostic catheterization. Coronary revascularization must be recommended only for patients
who would benefit in the absence of the planned surgery
1++ A
ppoFEV1 and ppoDLCO
ppoFEV1 should not to be used alone to select patients with lung cancer for lung resection, particularly patients
with moderate to severe COPD. It tends to underestimate the functional loss in the early postoperative phase and
does not appear a reliable predictor of complications in COPD patients. A ppoFEV1 value of 30% of predicted is
suggested as high risk threshold for this parameter when included in an algorithm for assessment of
pulmonary reserve before surgery
2+ C
DLCO should be routinely measured during pre-operative evaluation of lung resection candidates regardless of
whether the spirometric evaluation is abnormal. A ppoDLCO value of 30% of predicted is suggested as high risk
threshold for this parameter when included in an algorithm for assessment of pulmonary reserve before surgery
2++ B
The first estimate of residual lung function should be calculated based on segment counting. Only not
totally obstructed segments should be taken into account: the patency of bronchus (bronchoscopy) and segment
structure (CT scan) should be preserved.
2+ C
Patients with borderline function should need imaging-based calculation of residual lung function: ventilation
or perfusion scintigraphy, before pneumonectomy, or quantitative CT scan before lobectomy or pneumonectomy
2+ C
Exercise tests
Exercise tests should be indicated in all patients undergoing surgery for lung cancer with FEV1 or
DLCO under 80% of normal values
2++ B
Standardized symptom-limited stair climbing test is a cost-effective test capable to predict morbidity and
mortality after lung resection better than traditional spirometric values. It should be used as a first line
functional screening test to select those patients that can undergo safely to operation
(height of ascent > 22m) or those who need more sophisticated exercise tests in order to optimize their
perioperative management
2++ B
Shuttle walk test distance underestimates exercise capacity at the lower range and was not found to
discriminate between patients with and without complications. Thus, it should not be used alone to select
patients for operation. It could be used as a screening test: patients walking less than 400 m may have a
VO2 peak <15 ml/kg/min
2+ C
Cardiopulmonary exercise tests are performed in a controlled environment, reproducible and safe. Peak
VO2 measured during incremental exercise on treadmill or cycle should be regarded as the most important
parameter to consider, as a measure of exercise capacity and highly predictive of postoperative complications
2++ B
The following basic cut-off values for peak VO2 should be considered: peak VO2 >75% of predicted value
or 20 ml/kg/min qualifies for pneumonectomy; peak VO2 <35% or <10 ml/kg/min indicates high risk for
any resection. Evidence is thin to recommend cut-off values for lobectomy
2++ C
Admission to ICU
A systematic admission to ICU after thoracotomy should not be recommended 2++ C
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Table 1 (Continued )
Recommendations Level of
evidence
Grade of
recommendation
In the presence of appropriate high-dependency units (HDU) (intermediate care units), nobody
should be admitted to ICU on an elective basis. In an emergency basis, those patients requiring
support for organ failure (i.e. ventilatory mechanical assistance) should be admitted to ICU
2++ C
Patients undergoing complex pulmonary resections, those with marginal cardiopulmonary reserve
and those with moderate to high risk (see Table 2 ERJ paper) should be admitted to HDU
2++ C
After surgery, low risk patients should be sent to a dedicated thoracic surgical unit, and not to a
general surgical ward
2++ B
Induction treatment
After induction chemotherapy and/or radiotherapy a new functional evaluation (particularly DLCO)
before surgery should be recommended
2+ C
METS: metabolic equivalents; RCRI: Revised Cardiac Risk Index.leading multidisciplinary experts on functional evaluation of
lung cancer patients, was to develop up-to-date clinical
guidelines on fitness for surgery and chemoradiotherapy.
The subject was divided into different topics, which were
in turn assigned to at least two members of the task force.
The authors searched the literature according to their own
strategies; no central literature review was performed. The
draft reports written by the experts on each topic were then
reviewed, discussed, and voted by the entire expert panel.
The evidence supporting each recommendation was sum-
marized, and was graded as described by the Scottish
Intercollegiate Guidelines Network (SIGN) Grading Review
Group: grades of recommendation were based on the
strength of supporting evidence, taking into account itsFig. 1. Algorithm for assessment of cardiopulmonary reserve before lung resection in l
Respiratory Journal, 2009 [1]. FEV1: forced expiratory volume in one second. DLCO:
cardio-pulmonary exercise test.overall level and the considered judgment of the guideline
developers [2].
The following topicswerediscussed, and are summarized in
the final report along with graded recommendations: Cardi-
ologic evaluation before lung resection; lung function tests
and exercise tests (limitations of ppoFEV1; DLCO: systematic
or selective?; split function studies; exercise tests: systematic;
low-tech exercise tests; cardiopulmonary (high tech) exercise
tests); future trends in preoperative work-up; physiotherapy/
rehabilitation and smoking cessation; scoring systems;
advanced care management (ICU/HDU); quality of life in
patients submitted to radical treatment; combined cancer
surgery and lung volume reduction surgery; compromised
parenchymal sparing resections and minimally invasiveung cancer patients [reproduced with permission from Brunelli et al., European
diffusing lung capacity for carbon monoxide. VO2: oxygen consumption. CPET:
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functional reserve; neoadjuvant chemotherapy and complica-
tions; definitive chemo and radiotherapy: functional selection
criteria and definition of risk; should surgical criteria be re-
calibrated for radiotherapy?; the patient at prohibitive
surgical risk: alternatives to surgery;who should treat thoracic
patients and where these patients should be treated?
A summary of the most important recommendations is
reported in Table 1. We recommend readers to refer to the
primary publication [1] for a detailed background of these
levels of evidences.
Finally, all available information was integrated in a
functional algorithm for the preoperative evaluation of the
lung resection candidate. This algorithm was generated
based on the best available scientific evidence and consensus
opinion of experts (Fig. 1).
The algorithm emphasizes the importance of a preliminary
cardiologic assessment. Those patients at low cardiologic risk
or with an optimized cardiologic treatment may proceedwith
pulmonary evaluation. Complete spirometry and DLCO
assessment is recommended in all patients. All those patients
with either FEV1 or DLCO or both below 80% of predicted
should ideally undergo a formal cardiopulmonary exercise
test (CPET) with peak VO2 measurement. However, the group
recognized that many centers may have logistic problems in
systematically performing this test. In this latter circum-
stance, a low-technology exercise test, preferentially a stair
climbing test (or, as second choice, a shuttle walk test) may
be used as a screening test. Those patients showing sub-
optimal performance at these tests (<22 m at stair climbing)
should necessarily undergo a formal CPET.
Patients with peak VO2 lower than 35% of predicted value
or lower than 10 ml/kg/min and those with ppoFEV1 or
ppoDLCO or both lower than 30% of predicted values inassociation with ppoVO2 peak lower than 35% of predicted
value or lower than 10 ml/kg/min are to be regarded at
prohibitive risk for major lung resection (lobectomy or
pneumonectomy) and other therapeutic options should be
considered.
A certain proportion of lung resection candidates may be
unable to perform any type of reliable exercise test due to
concomitant incapacitating co-morbidities. As such patients
have been shown to have an increased risk of death after
major lung resection, after a careful selection based on the
available cardiac and pulmonary parameters, they should be
regarded as high-risk patients and monitored in an advanced
care management setting.
Although these guidelines were designed to be broadly
accepted, implemented and validated in all European
centers, the scientific evidence upon which they were based
were mainly generated in settings specialized in the
management of lung cancer patients. Based on best scientific
evidence, treatment of these patients outside specialized
settings or multidisciplinary environments is strongly dis-
couraged and application of our guidelines and recommen-
dations outside specialized centers is discouraged.
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